tiprankstipranks
Capricor Therapeutics announces Type B meeting with FDA for CAP-1002 program
PremiumThe FlyCapricor Therapeutics announces Type B meeting with FDA for CAP-1002 program
16d ago
Capricor Therapeutics to Present at Upcoming Investor Conferences
PremiumPress Releases
Capricor Therapeutics to Present at Upcoming Investor Conferences
2M ago
Capricor Therapeutics, Inc. Is Worried About This – Should You Be Worried Too?
PremiumCompany Announcements
Capricor Therapeutics, Inc. Is Worried About This – Should You Be Worried Too?
2M ago
Capricor Therapeutics Announces Upcoming Type-B Meeting with the FDA to Discuss Commercial Manufacturing Planning with an Aim to Expedite BLA Pathway for CAP-1002 in Duchenne Muscular Dystrophy
PremiumPress ReleasesCapricor Therapeutics Announces Upcoming Type-B Meeting with the FDA to Discuss Commercial Manufacturing Planning with an Aim to Expedite BLA Pathway for CAP-1002 in Duchenne Muscular Dystrophy
2M ago
Capricor announces company granted in-person Type-B meeting with FDA
PremiumThe Fly
Capricor announces company granted in-person Type-B meeting with FDA
2M ago
Is CAPR a Buy, Before Earnings?
PremiumPre-Earnings
Is CAPR a Buy, Before Earnings?
2M ago
Capricor initiated with an Overweight at Cantor Fitzgerald ahead of Phase 3 data
PremiumThe FlyCapricor initiated with an Overweight at Cantor Fitzgerald ahead of Phase 3 data
4M ago
Capricor Therapeutics initiated with an Overweight at Cantor Fitzgerald
PremiumThe Fly
Capricor Therapeutics initiated with an Overweight at Cantor Fitzgerald
4M ago
Capricor Therapeutics Announces Continuation of Phase 3 HOPE-3 Trial of CAP-1002 in Duchenne Muscular Dystrophy Based on Completion of Interim Futility Analysis
PremiumPress Releases
Capricor Therapeutics Announces Continuation of Phase 3 HOPE-3 Trial of CAP-1002 in Duchenne Muscular Dystrophy Based on Completion of Interim Futility Analysis
5M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100